Stock VTRS VIATRIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Viatris Inc.

Equities

VTRS

US92556V1061

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
11.57 USD +0.87% Intraday chart for Viatris Inc. +2.84% +6.83%
Apr. 18 Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says MT
Apr. 18 UK Regulator to Consider Undertakings for Theramex-Viatris Deal MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 10,374 22,488 16,363 13,497 12,992 13,740 - -
Enterprise Value (EV) 1 22,621 47,482 38,749 13,497 30,132 27,016 25,144 23,346
P/E ratio 670 x -16.9 x -12.9 x 6.51 x 217 x 7.99 x 13.3 x 15.7 x
Yield - - 3.33% - 4.43% 4.34% 4.52% 4.67%
Capitalization / Revenue 0.9 x 1.88 x 0.91 x 0.83 x 0.84 x 0.9 x 0.92 x 0.92 x
EV / Revenue 1.97 x 3.97 x 2.17 x 0.83 x 1.95 x 1.78 x 1.68 x 1.56 x
EV / EBITDA 6.39 x 13 x 6.03 x 2.34 x 5.88 x 5.53 x 5.34 x 4.98 x
EV / FCF 14.2 x 48 x 15.1 x - 12.4 x 10.9 x 9.46 x 9.38 x
FCF Yield 7.03% 2.08% 6.61% - 8.04% 9.16% 10.6% 10.7%
Price to Book 0.87 x 0.49 x 0.8 x - 0.64 x 0.65 x 0.62 x 0.58 x
Nbr of stocks (in thousands) 516,133 1,200,000 1,209,393 1,212,685 1,199,671 1,187,569 - -
Reference price 2 20.10 18.74 13.53 11.13 10.83 11.57 11.57 11.57
Announcement Date 2/27/20 3/1/21 2/28/22 2/27/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,500 11,946 17,886 16,263 15,427 15,219 14,984 14,974
EBITDA 1 3,540 3,654 6,426 5,777 5,124 4,885 4,709 4,692
EBIT 1 3,264 3,376 6,046 5,475 4,724 4,570 4,514 4,537
Operating Margin 28.38% 28.26% 33.8% 33.67% 30.63% 30.03% 30.13% 30.3%
Earnings before Tax (EBT) 1 154.4 -721.2 -664.4 2,813 202.9 4,100 955.3 1,035
Net income 1 16.8 -669.9 -1,269 2,079 54.7 1,885 989.2 875.6
Net margin 0.15% -5.61% -7.1% 12.78% 0.35% 12.39% 6.6% 5.85%
EPS 2 0.0300 -1.110 -1.050 1.710 0.0500 1.448 0.8670 0.7374
Free Cash Flow 1 1,590 988.8 2,560 - 2,423 2,475 2,658 2,488
FCF margin 13.83% 8.28% 14.31% - 15.7% 16.26% 17.74% 16.62%
FCF Conversion (EBITDA) 44.93% 27.06% 39.83% - 47.28% 50.67% 56.45% 53.03%
FCF Conversion (Net income) 9,467.26% - - - 4,428.88% 131.28% 268.72% 284.19%
Dividend per Share 2 - - 0.4500 - 0.4800 0.5025 0.5228 0.5403
Announcement Date 2/27/20 3/1/21 2/28/22 2/27/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 4,537 4,342 4,192 4,117 4,078 3,876 3,729 3,919 3,942 3,837 3,707 3,830 3,908 3,896 3,821
EBITDA 1 1,698 1,416 1,586 1,482 1,498 1,211 1,341 1,306 1,360 1,117 1,247 1,188 1,258 1,195 -
EBIT 1 1,609 1,314 1,551 1,425 1,415 1,085 1,254 1,226 1,257 986.6 1,101 1,139 1,191 1,125 1,131
Operating Margin 35.48% 30.26% 37% 34.6% 34.7% 27.99% 33.64% 31.29% 31.89% 25.71% 29.69% 29.73% 30.49% 28.87% 29.6%
Earnings before Tax (EBT) - -203.9 527.5 - - - - - 402.2 -855 - - - - -
Net income 1 311.5 -263.8 399.2 313.9 354.3 1,011 224.7 264 331.6 -765.6 122.6 143.6 188 187.6 -
Net margin 6.87% -6.08% 9.52% 7.62% 8.69% 26.09% 6.03% 6.74% 8.41% -19.95% 3.31% 3.75% 4.81% 4.82% -
EPS 2 0.2600 -0.2200 0.3300 0.2600 0.2900 0.8300 0.1900 0.2200 0.2700 -0.6400 0.1167 0.1405 0.2291 0.3038 -
Dividend per Share 2 0.1100 0.1100 0.1200 0.1200 0.1200 - 0.1200 0.1200 0.1200 0.1200 0.1248 0.1310 0.1310 0.1373 -
Announcement Date 11/8/21 2/28/22 5/9/22 8/8/22 11/7/22 2/27/23 5/8/23 8/7/23 11/7/23 2/28/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 12,247 24,994 22,386 - 17,140 13,275 11,404 9,606
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.46 x 6.84 x 3.484 x - 3.345 x 2.718 x 2.422 x 2.047 x
Free Cash Flow 1 1,591 989 2,560 - 2,423 2,475 2,658 2,489
ROE (net income / shareholders' equity) 19% 13.6% 20.6% - 17% 14.9% 15.1% 11%
ROA (Net income/ Total Assets) 7.13% 5.11% -2.18% - 0.11% 6.4% 1.6% 1.8%
Assets 1 235.6 -13,110 58,189 - 48,839 29,457 61,824 48,646
Book Value Per Share 2 23.00 38.20 16.90 - 17.00 17.80 18.80 19.90
Cash Flow per Share 2 3.490 2.050 2.500 - 2.320 2.320 2.410 2.640
Capex 1 213 243 457 - 377 434 424 452
Capex / Sales 1.85% 2.03% 2.56% - 2.44% 2.85% 2.83% 3.02%
Announcement Date 2/27/20 3/1/21 2/28/22 2/27/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Viatris Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
11.57 USD
Average target price
12.4 USD
Spread / Average Target
+7.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VIATRIS INC. Stock Viatris Inc.
+6.83% 13.74B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VTRS Stock
  4. Financials Viatris Inc.